透過您的圖書館登入
IP:3.144.93.73
  • 學位論文

紅番薯葉萃取物抑制脂肪細胞新生以及改善胰島素阻抗

Sweet potato leaves extracts inhibits adipogenesis and improves insulin resistance

摘要


肥胖是因為脂肪組織的過度增加而使食物攝取與能量消耗失去平衡。過去研究指出藉由降低脂肪細胞的增生及分化可以達到治療肥胖的效果。根據過去的文獻已知紅番薯葉萃取物含有高量的多酚,且被證實具有多方面的生物活性。本研究主要目的為探討紅番薯葉萃取物在活體外以及活體中所扮演的角色。細胞實驗中,首先利用 MTT 細胞存活性試驗與 BrdU 嵌入性測試探討紅番薯葉萃取物對於 3T3-L1 脂肪前驅細胞細胞增生的影響,結果指出紅番薯葉可以有效降低 3T3-L1 脂肪前驅細胞增生,並進一步利用西方墨點法發現紅番薯葉萃取物可以降低 3T3-L1 脂肪前驅細胞特異性蛋白 Preadipocyte factor-1 (Pref-1) 的表現量,接著利用測量胞內三酸甘油脂含量探究紅番薯葉萃取物對於 3T3-L1 脂肪前驅細胞細胞分化的影響,實驗發現,經過紅番薯葉萃取物前處理後,可以有效降低脂肪細胞分化。且由西方墨點法發現,紅番薯葉萃取物可以降低 3T3-L1 脂肪前驅細胞之分化轉錄因子 C/EBPα 的表現量,因此知道紅番薯葉萃取物可以有效降低 3T3-L1  脂肪前驅細胞細胞的增生及分化。動物實驗中,首先以高油脂飼料餵食 SD 大鼠 17 週,誘發胰島素阻抗,然後以口服方式餵食紅番薯葉萃取物,實驗結果顯示紅番薯葉萃取物可以加速改善高胰島素血症。 本研究結果顯示紅番薯葉萃取物可以抑制脂肪前驅細胞增生以及分化,且可以有效降低血液中胰島素濃度,因此紅番薯葉萃取物可能具有改善代謝症候群症狀的潛力。

並列摘要


Obesity is a condition characterized by an increase of adipose tissue as a result of positive imbalance between food intake and energy expenditure. Previous researches have suggested that decreased proliferation of preadipocytes and adipogenesis are target mechanisms to reduce obesity. Purple sweet potato leaves (PSPL) contain a high content of anti-oxidants which have been shown to exhibit a number of biological activities. This study was undertaken to check the role of purple sweet potato leaves (PSPL) extracts in vitro and in vivo. In vitro study showed that PSPL affects proliferation and adipogenesis of 3T3-L1 preadipocytes. PSPL extracts significantly decreased 3T3-L1 proliferation assessed by MTT and BrdU assays. Pre-treated 3T3-L1 preadipocytes with PSPL extracts prior to induced differentiation could reduce accumulation of triglyceride content in adipocytes. Western blot analysis of PSPL extract treated 3T3-L1 decreased Preadipocyte Factor 1 (Pref-1) and CCAAT/enhancer-binding proteins alpha (C/EBPα) expressions. Moreover, uptake of 2-NBDG in adipocytes were increased upon PSPL treatment. In vivo, PSPL could improve hyperinsulinemia condition of high fat diet induced insulin resistant rats. Our results indicate that the inhibition of preadipocytes population growth and adipogenesis in vitro and decreased plasma insulin concentration in vivo by PSPL might further alleviate effects on metabolic syndrome individuals.

參考文獻


行政院衛生署國民健康局 (2007). 成人(20歲以上)代謝症候群判定標準對照表.
Abate, N. (2000). Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications 14, 154-174.
Berger, J., and Moller, D.E. (2002). The mechanisms of action of PPARs. Annu Rev Med 53, 409-435.
Bjorntorp, P. (1992). Abdominal fat distribution and the metabolic syndrome. J Cardiovasc Pharmacol 20 Suppl 8, S26-28.
Boden, G., Chen, X., DeSantis, R.A., and Kendrick, Z. (1993). Effects of age and body fat on insulin resistance in healthy men. Diabetes Care 16, 728-733.

延伸閱讀